World Drug Sales Rose 7% In 1996, Says IMS

19 March 1997

Sales of medicinal products through retail pharmacies in the world's 10leading markets increased 7% during January-December 1996, to a total of $143.79 billion, according to IMS International. The biggest growth by market was reported for Italy, which was up 11% to $8.96 billion during the period, followed by the USA and the UK, both of which rose 10%, to $60.21 billion and $6.82 billion respectively.

Of the world's other biggest markets, sales in Japan increased 3% to $23.34 billion, Germany was up 5% to $16.52 billion and France advanced 2% to $15.02 billion. Sales in Europe's seven leading markets rose 6% to $56.49 billion.

By therapeutic category, the biggest sales increase reported during the period was for blood agents, which rose 16% to $7.92 billion worldwide, followed by parasitologicals, up 15% to $283 million and central nervous system products, with sales advancing 14% to $20.29 billion. Cytostatics were up 12% to $3.93 billion and diagnostic agents advanced 10% to $1.76 billion.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight